Rapid Influenza Diagnostic Tests (RIDT) Market
By Test;
Traditional Diagnostic Test, Molecular Diagnostic Tests, and OthersBy Type;
Type A Flu, Type B Flu, and Type C FluBy Molecular;
PCR, INAAT- NASBAT, and TMABASBy Product Type;
RIDT For Influenza A and RIDT for Influenza BBy End-Use;
Hospitals, Diagnostics Centers, Research Laboratories, and OthersBy Geography;
North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)Rapid Influenza Diagnostic Tests (RIDT) Market Overview
Rapid Influenza Diagnostic Tests (RIDT) Market (USD Million)
Rapid Influenza Diagnostic Tests (RIDT) Market was valued at USD 1,260.35 million in the year 2024. The size of this market is expected to increase to USD 2,223.80 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 8.5%.
Rapid Influenza Diagnostic Tests (RIDT) Market
*Market size in USD million
CAGR 8.5 %
Study Period | 2025 - 2031 |
---|---|
Base Year | 2024 |
CAGR (%) | 8.5 % |
Market Size (2024) | USD 1,260.35 Million |
Market Size (2031) | USD 2,223.80 Million |
Market Concentration | Medium |
Report Pages | 300 |
Major Players
- Roche Diagnostics
- Abbott Laboratories
- Quidel Corporation
- Thermo Fisher Scientific
- BD (Becton, Dickinson and Company)
- DiaSorin
- Luminex Corporation
- Meridian Bioscience
- Cepheid
- Sekisui Diagnostics
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Rapid Influenza Diagnostic Tests (RIDT) Market
Fragmented - Highly competitive market without dominant players
The Rapid Influenza Diagnostic Tests (RIDT) Market is gaining momentum as healthcare providers increasingly rely on fast and efficient point-of-care diagnostics. With more than 65% of medical institutions turning to RIDTs, the emphasis on reducing diagnostic wait times and improving patient care is evident. This shift is opening fresh opportunities for product innovation and technological expansion across medical settings. The market is evolving with a strong focus on streamlined testing solutions and cost-effective strategies.
Influenza’s Growing Impact Sparks Innovation
As over 70% of flu-related screenings depend on immediate results, RIDTs play a pivotal role in early detection. The rising burden of seasonal influenza has prompted continual innovation in test design and delivery. Many companies are deploying targeted strategies involving collaboration with research groups to launch highly sensitive formats. These efforts are reinforcing the market’s growth trajectory and building a strong future outlook for diagnostic solutions.
Boost from Emerging Diagnostic Technologies
Innovative molecular RIDTs are now delivering over 60% higher accuracy, driving broader acceptance in clinical practice. These technological advancements are pushing stakeholders to refine their growth strategies by investing in automation and precision tools. The increase in digital testing platforms reflects a broader industry push toward streamlined operations and smarter diagnostics, ensuring better patient outcomes.
Promising Market Expansion Pathways
The Rapid Influenza Diagnostic Tests (RIDT) Market is on a promising growth path, with usage expected to exceed 75% across healthcare systems. Stakeholders are proactively exploring opportunities to boost output, optimize delivery channels, and enhance diagnostic availability. Supported by continuous technological evolution, solid partnership models, and increasing demand, the sector's expansion and future growth potential remain strong.
Rapid Influenza Diagnostic Tests (RIDT) Market Recent Developments
-
In 2021, The acquisition of Luminex Corporation, a business involved in the development of diagnostic tools for infectious diseases, was announced by DiaSorin SpA. This acquisition aimed to increase the diagnostic goods available in the United States, including those for the diagnosis of influenza. This tactical choice helped the business grow its clientele and strengthen its position in the market.
-
In May 2021 Becton, Dickinson and Company (US) received FDA approval for the BD Veritor Plus System, which is used to detect SARS-CoV-2, influenza A, and influenza B.
Rapid Influenza Diagnostic Tests (RIDT) Market Segment Analysis
In this report, the Rapid Influenza Diagnostic Tests (RIDT) Market has been segmented by Test, Type, Molecular, Product Type, End-Use, and Geography.
Rapid Influenza Diagnostic Tests (RIDT) Market, Segmentation by Test
The segmentation of the Rapid Influenza Diagnostic Tests (RIDT) Market by Test into Traditional Diagnostic Test, Molecular Diagnostic Tests, and Other Molecular Test.
Traditional Diagnostic Test
Traditional Diagnostic Tests account for approximately 45% of the Rapid Influenza Diagnostic Tests (RIDT) Market. These tests are valued for their low cost and quick turnaround times, typically delivering results within 15-30 minutes. Despite moderate sensitivity, they remain widely used in primary care settings.
Molecular Diagnostic Tests
Molecular Diagnostic Tests hold around 40% of the market share and are gaining traction due to their higher sensitivity and accuracy compared to traditional methods. These tests leverage nucleic acid amplification techniques and are increasingly adopted in hospital laboratories and specialized diagnostic centers.
Other Molecular Test
Other Molecular Tests make up the remaining 15% of the market. This category includes emerging technologies such as CRISPR-based diagnostics and microarray platforms that offer high precision and are under evaluation for broader commercial deployment in clinical diagnostics.
Rapid Influenza Diagnostic Tests (RIDT) Market, Segmentation by Type
The segmentation of the Rapid Influenza Diagnostic Tests (RIDT) Market by Type into Type A Flu, Type B Flu, and Type C Flu.
Type A Flu
Type A Flu dominates the Rapid Influenza Diagnostic Tests (RIDT) Market, accounting for nearly 60% of total test usage. Due to its potential for seasonal outbreaks and pandemic risks, diagnostic focus remains high. RIDTs targeting Type A offer rapid detection to support timely public health response.
Type B Flu
Type B Flu contributes to approximately 30% of the RIDT market. It is commonly associated with seasonal influenza in children and adolescents. Although less severe than Type A, accurate and early diagnosis remains essential for appropriate antiviral treatment and containment.
Type C Flu
Type C Flu represents a smaller portion—around 10%—of the market, as it generally causes mild respiratory symptoms and rarely results in epidemics. RIDTs for Type C are less prevalent but gaining interest in research applications and academic studies focusing on viral evolution.
Rapid Influenza Diagnostic Tests (RIDT) Market, Segmentation by Molecular
The segmentation of the Rapid Influenza Diagnostic Tests (RIDT) Market by Molecular into PCR, INAAT- NASBAT, and TMABAS.
PCR
PCR (Polymerase Chain Reaction) is the most widely used molecular technique in the RIDT market, contributing to over 65% of molecular diagnostic applications. Known for its high sensitivity and specificity, PCR allows for early detection of influenza strains, making it ideal for hospital and laboratory settings.
INAAT-NASBAT
INAAT-NASBAT (Isothermal Nucleic Acid Amplification Technology – Nucleic Acid Sequence-Based Amplification Test) accounts for around 20% of molecular RIDT usage. This technique provides rapid amplification without the need for thermal cycling, offering faster results in point-of-care diagnostics.
TMABAS
TMABAS is an emerging molecular platform in the RIDT space, currently holding less than 15% of the market share. It is gaining attention for its compact design and potential for automated, high-throughput testing, particularly in mobile and remote care settings.
Rapid Influenza Diagnostic Tests (RIDT) Market, Segmentation by Product Type
The segmentation of the Rapid Influenza Diagnostic Tests (RIDT) Market by Product Type into RIDT for Influenza A and RIDT for Influenza B
RIDT for Influenza A
RIDT for Influenza A dominates the market, accounting for approximately 60% of the total product type segment. These tests are highly preferred due to the higher prevalence and more severe clinical manifestations associated with Influenza A infections, especially during seasonal outbreaks and pandemics.
RIDT for Influenza B
RIDT for Influenza B holds about 40% of the market share, playing a crucial role in diagnosing milder yet significant flu strains. Though less aggressive than Influenza A, timely detection using RIDTs helps reduce disease transmission and improves clinical outcomes, especially in pediatric and elderly populations.
Rapid Influenza Diagnostic Tests (RIDT) Market, Segmentation by End-Use
The Rapid Influenza Diagnostic Tests (RIDT) Market is segmented by end-use into Hospitals, Diagnostics Centers, Research Laboratories, and Others
Hospitals
Hospitals account for over 45% of the RIDT market share due to their role as primary centers for flu diagnosis and treatment. The integration of point-of-care testing in emergency and outpatient departments enables rapid detection and immediate care, especially during flu seasons and outbreaks.
Diagnostics Centers
Diagnostics Centers contribute approximately 30% to the market, offering specialized infrastructure for high-volume testing. These centers provide accurate and quick results, making them a key component in community-wide screening and early disease identification.
Research Laboratories
Research Laboratories represent around 15% of the market, focusing on the development and validation of innovative RIDTs. They also play a pivotal role in analyzing viral mutations and improving test sensitivity and specificity over time.
Others
Others include pharmacies, academic institutions, and mobile testing units, holding the remaining 10% share. Their involvement in remote testing initiatives and public health campaigns is growing, particularly in underserved and rural areas.
Rapid Influenza Diagnostic Tests (RIDT) Market, Segmentation by Geography
In this report, the Rapid Influenza Diagnostic Tests (RIDT) Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East & Africa and Latin America.
Regions and Countries Analyzed in this Report
Rapid Influenza Diagnostic Tests (RIDT) Market Share (%), by Geographical Region
North America
North America dominates the Rapid Influenza Diagnostic Tests (RIDT) market, accounting for nearly 40% of the global revenue share. The region’s high adoption of advanced diagnostic tools, strong healthcare infrastructure, and frequent influenza outbreaks contribute significantly to market growth.
Europe
Europe holds around 25% of the market share, driven by increasing government initiatives for early flu detection and prevention. Countries like Germany and the UK are investing in rapid testing programs across healthcare and public settings to reduce seasonal influenza burden.
Asia Pacific
Asia Pacific is witnessing robust growth with a market share of about 20%, supported by a rising population, growing awareness, and expansion of diagnostic laboratories. Developing nations such as India and China are focusing on enhancing point-of-care testing capabilities.
Middle East & Africa
Middle East & Africa represents roughly 8% of the global RIDT market. While the region is still in its early phase of diagnostic infrastructure development, increased healthcare investments and international aid are accelerating market penetration.
Latin America
Latin America contributes about 7% to the overall market, with Brazil and Mexico leading in terms of testing deployment. Efforts to combat flu outbreaks through public health initiatives are supporting the gradual uptake of RIDT technologies.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Rapid Influenza Diagnostic Tests (RIDT) Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers
- Seasonal outbreaks demand
- Rapid result necessity
- Public health awareness
- Point-of-care convenience
-
Technological advancements : Technological advancements stand as a significant driver in the Global Rapid Influenza Diagnostic Tests (RIDT) Market. The continual improvement and innovation in diagnostic technologies have led to the development of more accurate, sensitive, and user-friendly rapid influenza tests. Advancements such as improved assay sensitivity and specificity, enhanced viral detection capabilities, and reduced turnaround times have significantly contributed to the market's growth. Moreover, the integration of advanced features like point-of-care connectivity, automated result interpretation, and data management functionalities has further enhanced the utility and adoption of rapid influenza diagnostic tests across healthcare settings.
Additionally, technological advancements have facilitated the development of multiplexed testing solutions, allowing simultaneous detection of multiple influenza strains and respiratory pathogens. This capability is particularly valuable during influenza seasons and pandemic outbreaks, enabling comprehensive respiratory tract infection diagnosis and management. The ongoing research and development efforts in the field of rapid influenza testing continue to drive innovation, with emerging technologies such as nucleic acid amplification tests (NAATs), microfluidic platforms, and digital immunoassays poised to further revolutionize influenza diagnostics.
Furthermore, technological advancements in rapid influenza testing have led to the emergence of next-generation RIDTs that offer improved accuracy, sensitivity, and specificity compared to conventional methods. These next-gen tests leverage innovative assay designs, target amplification techniques, and advanced detection technologies to enhance viral detection limits and reduce false-negative results. The continuous evolution and adoption of cutting-edge technologies in rapid influenza testing underscore the market's potential for addressing seasonal influenza challenges, pandemic threats, and the growing demand for point-of-care diagnostics in healthcare settings.
Restraints
- Accuracy concerns persist
- Regulatory compliance challenges
- Cost implications affect
- Variability in performance
-
Emerging competitor pressures : One of the notable restraints in the Global Rapid Influenza Diagnostic Tests (RIDT) Market is the emerging competitor pressures. As the market for rapid influenza tests continues to expand, it attracts a growing number of players, leading to heightened competition. This competitive landscape poses challenges such as pricing pressures, market saturation, and the need for differentiation among products. Market players face the task of distinguishing their offerings through technological innovations, performance enhancements, and strategic partnerships to maintain a competitive edge in the rapidly evolving RIDT market.
Moreover, emerging competitors in the RIDT market may introduce disruptive technologies or alternative testing approaches, posing a threat to established players. These newcomers often leverage advancements in molecular diagnostics, nucleic acid amplification techniques, or novel assay formats to challenge traditional rapid influenza testing methods. The presence of multiple competitors vying for market share intensifies the competitive dynamics and drives continuous innovation and differentiation strategies among market participants.
Furthermore, competitor pressures in the RIDT market necessitate ongoing investments in research and development, marketing strategies, and regulatory compliance efforts. Established players must navigate the competitive landscape by addressing customer needs, adapting to market trends, and enhancing product offerings to remain competitive. Collaboration and strategic alliances with industry partners, healthcare providers, and regulatory authorities also play a crucial role in mitigating competitor pressures and sustaining growth in the Global Rapid Influenza Diagnostic Tests Market.
Opportunities
- Pandemic preparedness initiatives
- Emerging markets expansion
- Integration with telemedicine
- Multiplexed testing development
-
Ongoing R&D innovations : Ongoing research and development (R&D) innovations represent a significant opportunity in the Global Rapid Influenza Diagnostic Tests (RIDT) Market. Market players focus on developing next-generation rapid influenza tests with enhanced accuracy, sensitivity, and specificity, addressing the limitations of conventional RIDTs. Innovations in assay design, target amplification techniques, and detection technologies contribute to improved viral detection limits, reduced false-negative results, and enhanced diagnostic performance. These R&D efforts drive technological advancements and pave the way for novel testing solutions that meet evolving market demands and clinical needs.
Furthermore, the integration of rapid influenza testing with telemedicine presents an opportunity to expand access to diagnostic services and improve patient care delivery. Telemedicine platforms enable remote consultations, virtual healthcare services, and remote monitoring capabilities, offering a convenient and efficient way to conduct rapid influenza tests and share results with healthcare providers. The integration of RIDTs with telemedicine platforms enhances healthcare accessibility, particularly in underserved or remote areas, and facilitates timely diagnosis, treatment, and disease management for influenza patients.
Moreover, multiplexed testing development represents a promising opportunity in the Global Rapid Influenza Diagnostic Tests Market. Multiplexed tests allow simultaneous detection of multiple influenza strains, respiratory pathogens, or co-infections, providing comprehensive diagnostic information in a single test. This capability is valuable in clinical decision-making, outbreak surveillance, and epidemiological studies, enhancing healthcare providers' ability to identify and manage influenza outbreaks effectively. The ongoing advancements in multiplexed testing technologies and assay platforms contribute to expanded testing capabilities, improved diagnostic accuracy, and optimized patient care outcomes in the rapid influenza testing landscape.
Competitive Landscape Analysis
Key players in Global Rapid Influenza Diagnostic Tests (RIDT) Market include :
- Roche Diagnostics
- Abbott Laboratories
- Quidel Corporation
- Thermo Fisher Scientific
- BD (Becton, Dickinson and Company)
- DiaSorin
- Luminex Corporation
- Meridian Bioscience
- Cepheid
- Sekisui Diagnostics
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Test
- Market Snapshot, By Type
- Market Snapshot, By Molecular
- Market Snapshot, By Product Type
- Market Snapshot, By End-Use
- Market Snapshot, By Region
- Rapid Influenza Diagnostic Tests (RIDT) Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Seasonal outbreaks demand
- Rapid result necessity
- Public health awareness
- Point-of-care convenience
- Technological advancements
- Restraints
- Accuracy concerns persist
- Regulatory compliance challenges
- Cost implications affect
- Variability in performance
- Emerging competitor pressures
- Opportunities
- Pandemic preparedness initiatives
- Emerging markets expansion
- Integration with telemedicine
- Multiplexed testing development
- Ongoing R&D innovations
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Rapid Influenza Diagnostic Tests (RIDT) Market,By Test, 2021 - 2031 (USD Million)
- Traditional Diagnostic Test
- Molecular Diagnostic Tests
- Others
- Rapid Influenza Diagnostic Tests (RIDT) Market,By Type, 2021 - 2031 (USD Million)
- Type A Flu
- Type B Flu
- Type C Flu
- Rapid Influenza Diagnostic Tests (RIDT) Market,By Molecular, 2021 - 2031 (USD Million)
- PCR
- INAAT- NASBAT
- TMABAS
- Rapid Influenza Diagnostic Tests (RIDT) Market,By Product Type, 2021 - 2031 (USD Million)
- RIDT for Influenza A
- RIDT for Influenza B
- Rapid Influenza Diagnostic Tests (RIDT) Market, By End-Use, 2021 - 2031 (USD Million)
- Hospitals
- Diagnostics centers
- Research laboratories
- Others
- Rapid Influenza Diagnostic Tests (RIDT) Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Rapid Influenza Diagnostic Tests (RIDT) Market,By Test, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Roche Diagnostics
- Abbott Laboratories
- Quidel Corporation
- Thermo Fisher Scientific
- BD (Becton, Dickinson and Company)
- DiaSorin
- Luminex Corporation
- Meridian Bioscience
- Cepheid
- Sekisui Diagnostics
- Company Profiles
- Analyst Views
- Future Outlook of the Market